BR0208828A - Immediate release pharmaceutical formulation, process for preparing a formulation, solid pharmaceutical composition, process for forming a composition, use of a formulation, and method of prophylaxis or treatment of an arrhythmia - Google Patents

Immediate release pharmaceutical formulation, process for preparing a formulation, solid pharmaceutical composition, process for forming a composition, use of a formulation, and method of prophylaxis or treatment of an arrhythmia

Info

Publication number
BR0208828A
BR0208828A BR0208828-2A BR0208828A BR0208828A BR 0208828 A BR0208828 A BR 0208828A BR 0208828 A BR0208828 A BR 0208828A BR 0208828 A BR0208828 A BR 0208828A
Authority
BR
Brazil
Prior art keywords
formulation
composition
immediate release
diazabicyclo
butyl
Prior art date
Application number
BR0208828-2A
Other languages
Portuguese (pt)
Inventor
Cristina Hovdal
Anna Lundgren
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0208828A publication Critical patent/BR0208828A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"FORMULAçãO FARMACêUTICA DE LIBERAçãO IMEDIATA, PROCESSO PARA A PREPARAçãO DE UMA FORMULAçãO, COMPOSIçãO FARMACêUTICA SóLIDA, PROCESSO PARA A FORMAçãO DE UMA COMPOSIçãO, USO DE UMA FORMULAçãO, E, MéTODO DE PROFILAXIA OU TRATAMENTO DE UMA ARRITMIA". São fornecidas formulações farmacêuticas de liberação imediata compreendendo, como o ingrediente ativo, 4-({3-[7-(3,3-dimetil-2-oxobutil)-9-oxa-3,7-diazabiciclo[3,3, 1 ]non-3-il]propil} amino)-benzonitrila, 2-{7-[3-(4-cianoanilino)propil]-9-oxa-3,7-diazabiciclo[3,3,1] non-3-il}etilcarbamato de terc-butila, 2-{7-[4-(4-cianofenil)butil]-9-oxa3,7-diazabiciclo[3,3,1]non-3-il}etilcar bamato de terc-butila ou 2-{7-[(2S)-3-(4-cianofenóxi)-2-hidroxipropil]-9-oxa-3,7-diazabiciclo-[3, 3,1]non-3il} etilcarbamato de terc-butila ou um sal farmaceuticamente aceitável de qualquer um destes compostos e um diluente ou veículo farmaceuticamente aceitáveis. Ainda são fornecidas composições farmacêuticas sólidas compreendendo um ingrediente ativo estabelecido acima, cujas composições são adequadas para a preparação de formulações farmacêuticas de liberação imediata e cujas composições podem ser preparadas, por exemplo, pela secagem por congelamento. As formulações e as composições são úteis na profilaxia e/ou tratamento de arritmias cardíacas."PHARMACEUTICAL FORMULATION OF IMMEDIATE RELEASE, PROCESS FOR PREPARING A FORMULATION, SOLID PHARMACEUTICAL COMPOSITION, PROCESS FOR FORMATION OF A COMPOSITION, AND USE OF A FORMULA OR PROPHYAL METHOD. Immediate release pharmaceutical formulations are provided comprising as the active ingredient 4 - ({3- [7- (3,3-dimethyl-2-oxobutyl) -9-oxa-3,7-diazabicyclo [3,3,1] ] non-3-yl] propyl} amino) benzonitrile, 2- {7- [3- (4-cyanoanilino) propyl] -9-oxa-3,7-diazabicyclo [3,3,1] non-3- tert-butyl yl} ethylcarbamate, 2- {7- [4- (4-cyanophenyl) butyl] -9-oxa3,7-diazabicyclo [3,3,1] non-3-yl} ethyl tert-butyl carbamate or tert-butyl 2- {7 - [(2S) -3- (4-cyanophenoxy) -2-hydroxypropyl] -9-oxa-3,7-diazabicyclo- [3,1,1] non-3yl} ethylcarbamate or a pharmaceutically acceptable salt of any of these compounds and a pharmaceutically acceptable diluent or carrier. Further provided are solid pharmaceutical compositions comprising an active ingredient set forth above, whose compositions are suitable for the preparation of immediate release pharmaceutical formulations and whose compositions may be prepared, for example, by freeze drying. The formulations and compositions are useful in the prophylaxis and / or treatment of cardiac arrhythmias.

BR0208828-2A 2001-04-12 2002-04-12 Immediate release pharmaceutical formulation, process for preparing a formulation, solid pharmaceutical composition, process for forming a composition, use of a formulation, and method of prophylaxis or treatment of an arrhythmia BR0208828A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101329A SE0101329D0 (en) 2001-04-12 2001-04-12 Pharmaceutical formulation
PCT/SE2002/000726 WO2002083689A1 (en) 2001-04-12 2002-04-12 3,7-diazabicyclo [3.3.1] formulations as anti-arrythmic compounds

Publications (1)

Publication Number Publication Date
BR0208828A true BR0208828A (en) 2004-03-09

Family

ID=20283785

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0208828-2A BR0208828A (en) 2001-04-12 2002-04-12 Immediate release pharmaceutical formulation, process for preparing a formulation, solid pharmaceutical composition, process for forming a composition, use of a formulation, and method of prophylaxis or treatment of an arrhythmia

Country Status (26)

Country Link
US (1) US20050037067A1 (en)
EP (1) EP1389212B1 (en)
JP (1) JP2005500262A (en)
KR (1) KR20030088498A (en)
CN (1) CN1514839A (en)
AR (1) AR035806A1 (en)
AT (1) ATE332902T1 (en)
BG (1) BG108234A (en)
BR (1) BR0208828A (en)
CA (1) CA2443473A1 (en)
CZ (1) CZ20032774A3 (en)
DE (1) DE60213084T2 (en)
EE (1) EE200300495A (en)
HU (1) HUP0303486A3 (en)
IL (1) IL158033A0 (en)
IS (1) IS6989A (en)
MX (1) MXPA03009209A (en)
NO (1) NO20034529L (en)
NZ (1) NZ528561A (en)
PL (1) PL366629A1 (en)
RU (1) RU2003129230A (en)
SE (1) SE0101329D0 (en)
SK (1) SK12562003A3 (en)
TW (1) TWI257391B (en)
WO (1) WO2002083689A1 (en)
ZA (1) ZA200307756B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259836B (en) * 2001-04-12 2006-08-11 Astrazeneca Ab Modified release formulation suitable for antiarrhythmic compounds
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
GB0523810D0 (en) * 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
JP5235676B2 (en) * 2005-12-20 2013-07-10 レツク・フアーマシユーテイカルズ・デー・デー (E) -7- [4- (4-Fluorophenyl) -6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl]-(3R, 5S) -3,5-dihydroxyhepta Pharmaceutical composition comprising 6-enoic acid
US20080085303A1 (en) * 2006-10-10 2008-04-10 Penwest Pharmaceuticals Co. Robust sustained release formulations of oxymorphone and methods of use thereof
US20090142398A1 (en) * 2007-11-21 2009-06-04 Pharmascience Inc. Novel pharmaceutical compositions comprising a disintegration matrix
DE102008047910A1 (en) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tabletting excipient based on lactose and cellulose
WO2014157603A1 (en) * 2013-03-29 2014-10-02 アステラス製薬株式会社 Pharmaceutical composition for oral administration

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3732094A1 (en) * 1987-09-24 1989-04-06 Basf Ag BISPID DERIVATIVES AS CLASS III ANTIARRHYTHMICS
US5110933A (en) * 1989-11-13 1992-05-05 Board Of Regents Of Oklahoma State University Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof
DE4402933A1 (en) * 1994-02-01 1995-08-03 Kali Chemie Pharma Gmbh New drugs containing 3-benzoyl-3,7-diazabicyclo [3,3,1] nonane compounds
SE9704709D0 (en) * 1997-12-17 1997-12-17 Astra Ab Pharmaceutically active compounds
NZ514477A (en) * 1999-04-09 2003-04-29 Astrazeneca Ab Adamantane derivatives
SE9903759D0 (en) * 1999-10-18 1999-10-18 Astra Ab Pharmaceutically active compounds
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent

Also Published As

Publication number Publication date
WO2002083689A1 (en) 2002-10-24
NZ528561A (en) 2005-03-24
EP1389212A1 (en) 2004-02-18
CA2443473A1 (en) 2002-10-24
AR035806A1 (en) 2004-07-14
CZ20032774A3 (en) 2004-01-14
NO20034529D0 (en) 2003-10-09
SE0101329D0 (en) 2001-04-12
US20050037067A1 (en) 2005-02-17
KR20030088498A (en) 2003-11-19
DE60213084T2 (en) 2007-01-11
IS6989A (en) 2003-10-10
DE60213084D1 (en) 2006-08-24
MXPA03009209A (en) 2004-01-29
IL158033A0 (en) 2004-03-28
NO20034529L (en) 2003-12-08
TWI257391B (en) 2006-07-01
RU2003129230A (en) 2005-04-10
EE200300495A (en) 2003-12-15
PL366629A1 (en) 2005-02-07
HUP0303486A3 (en) 2005-04-28
JP2005500262A (en) 2005-01-06
HUP0303486A2 (en) 2004-01-28
ATE332902T1 (en) 2006-08-15
BG108234A (en) 2005-04-30
CN1514839A (en) 2004-07-21
EP1389212B1 (en) 2006-07-12
ZA200307756B (en) 2005-01-03
SK12562003A3 (en) 2004-03-02

Similar Documents

Publication Publication Date Title
CA2233285A1 (en) Pyrazolopyrimidines as crf receptor antagonists
BR0208829A (en) Pharmaceutically acceptable salt, compound, processes for preparing a salt, compound and crystalline form of the compounds, pharmaceutical formulation, use of a compound, and method of prophylaxis or treatment of an arrhythmia.
SE9904508D0 (en) New compounds
BR0317294A (en) Compound, pharmaceutical formulation, use of a compound, methods for prevention and / or treatment of conditions associated with glycogen synthase kinase-3 and disease prevention and / or treatment, and use of intermediates
FI900085A (en) Process for Preparing Therapeutically Useful N- (Pyrimidine and Condensed Pyrimidin-4-One) Ethyl-Piperidine and Piperinated Zine Derivatives
PH25504A (en) Novel substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides pharmaceutical composition containing said compound, method of use thereof
CO5631443A2 (en) DERIVATIVES OF 7-ARIL-3,9-DIAZABICICLO (3.3.1) NON-6-ENO AND ITS USE AS RHENINE INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES
WO2006016067A3 (en) Pyrido-pyrido pyrimidine derivatives, preparation thereof, therapeutic use thereof for treating cancer
DE69131759D1 (en) Substituted 4H-pyrido- (1,2-a) pyrimidin-4-ones at positions 2 and 9
BR0208828A (en) Immediate release pharmaceutical formulation, process for preparing a formulation, solid pharmaceutical composition, process for forming a composition, use of a formulation, and method of prophylaxis or treatment of an arrhythmia
NO172645C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 2-AMINOPYRIMIDINON DERIVATIVES
BR0315958A (en) Compound, pharmaceutical composition, process for preparing a compound, new intermediates and use of the compound
IL148874A0 (en) Sulfonyl amino acid derivatives, their preparation and pharmaceutical compositions containing them
BR0114366A (en) Compound, pharmaceutical formulation, use of a compound, method of prophylaxis or treatment of an arrhythmia and process for the preparation of a compound
WO2002000166A3 (en) New compounds useful as antibacterial agents
BR0208830A (en) Modified release pharmaceutical composition, process for preparing a composition, use of a composition, and method of prophylaxis or treatment of an arrhythmia
SE9803517D0 (en) Pharmaceutical preparation
MY101266A (en) Pharmaceutical formulations
TH60987A (en) New pharmaceutical formulation suitable for cardiac arrhythmias.
EA200400864A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 2- (4-ETOXYPHENYL) -3- (4-METHESULPHONYLPHENYL) PYRAZOLO [1,5-b] PYRIDAZIN IN THE FORM OF NANOPARTICLES
PT1010694E (en) SPIROIMIDAZOLINIC DERIVATIVES AND THEIR USE AS ALPHA-ADRENERGIC ANTAGONISTS AND BLOCKERS OF MONOAMINES RECAPTURE

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2055 DE 25/05/2010.